Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 28 of 721 for:    Botulinum Toxins, Type A

A Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A in Patients With Overactive Bladder (OAB)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02786407
Recruitment Status : Enrolling by invitation
First Posted : June 1, 2016
Last Update Posted : January 3, 2018
Sponsor:
Information provided by (Responsible Party):
Lanzhou Institute of Biological Products Co., Ltd

Brief Summary:
This is a multicenter, double-blind, randomized, placebo-controlled study designed to evaluate the efficacy and safety of Botulinus Toxin Type A for Injection (HengLi®) in patients with overactive bladder (OAB) . Approximately 216 subjects will be enrolled. Subjects will be randomized 2:1 to receive intradetrusor injection of Botulinus Toxin Type A for Injection (HengLi®) 100 U or placebo. The study contains two parts: core double-blinded phase and extension phase. In the core double-blinded phase, eligible subjects must attend three study visits posttreatment 12 weeks. During the extension phase, subjects must also attend three study visits (12 weeks). The primary efficacy variables is the change from baseline in the daily average frequency of micturition at week 6 after the first treatment.A 3-day paper bladder diary will be used before each study visits (screening period, the second week, the sixth week, the twelfth week, the fourteenth week, the eighteenth week and the twenty fourth week ) to collect all OAB symptoms (episodes of urgency, incontinence, micturition and nocturia) and volume per voidSafety parameters will also be measured, including adverse events, vital signs (pulse and blood pressure) and clinical laboratory tests (haematology, serum chemistry and urinanalysis).

Condition or disease Intervention/treatment Phase
Overactive Bladder Drug: Botulinum Toxin Type A for Injection Drug: Placebo Phase 3

Detailed Description:
Eligible patients will be randomized on day 1 to receive double-blind treatment with Botulinus Toxin Type A for Injection (HengLi®) 100U or placebo in a 2:1 ratio. A total of 216 subjects will be randomized into this study. Followup visits will occur at day 0, week 6 and 12, and week 14, 18 and 24 thereafter until study exit at week 24 unless re-treatment was necessary. The primary efficacy variables is the change from baseline in the daily average frequency of micturition at week 6. After a screening period of 1 week, all eligible patients will be randomized to receive a single intramuscular treatment with Botulinus Toxin Type A for Injection (HengLi®) or placebo at day 0 (visit 0).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 216 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A for Injection in Chinese Subjects With Overactive Bladder (OAB)
Study Start Date : March 2016
Estimated Primary Completion Date : November 2018
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Botulinum Toxin Type A for Injection
Botulinum Toxin Type A is a specific formulation of a locally injected muscle relaxant whose active ingredient is botulinum toxin type A produced by clostridium botulinum A strain Hall. Excipients contain sucrose,dextran and gelatin.
Drug: Botulinum Toxin Type A for Injection
In these studies,patients received a minimum intramuscular(IM) dose of 100U of Botulinum Toxin Type A administered to 20 injection sites
Other Name: HengLi®

Placebo Comparator: Placebo
The placebo does not include botulinum toxin A ,but include sucrose,dextran and gelatin.
Drug: Placebo
In these studies,patients received placebo administered to 20 injection sites




Primary Outcome Measures :
  1. average frequency of micturition [ Time Frame: Baseline(week -1 to 0)and core phase(week 6) ]
    The primary efficacy variables is the change from baseline in the daily average frequency of micturition at week 6 after the first treatment.


Secondary Outcome Measures :
  1. The change from baseline in the daily average frequency of urgency episodes and the scores. [ Time Frame: Baseline and Week 2,6,12,14,18,24 ]
    The degree of urgency is divided into 5 grades (With 0 points representing no hurry, hurry on behalf of 5 points, 1~5 points gradually increase depending on the degree of urgency)

  2. average frequency of UI episodes [ Time Frame: Baseline and Week 2,6,12,14,18,24 ]
    The change from baseline in the daily average frequency of UI episodes

  3. volume per micturition [ Time Frame: Baseline and Week 2,6,12,14,18,24 ]
    The change from baseline in volume voided per micturition

  4. maximum cystometric capacity (MCC) [ Time Frame: Baseline(week -1 to 0)and core phase(week 6) ]
    The change from baseline in MCC at week 6 after the first treatment ( Only in patients with neurogenic overactive bladder )

  5. maximum detrusor pressure during first involuntary detrusor contraction (PdetmaxIDC) [ Time Frame: Baseline(week -1 to 0)and core phase(week 6) ]
    The change from baseline in PdetmaxIDC at week 6 after the first treatment ( Only in patients with neurogenic overactive bladder )

  6. volume at first IDC (VPmaxIDC) [ Time Frame: Baseline(week -1 to 0)and core phase(week 6) ]
    The change from baseline in VPmaxIDC at week 6 after the first treatment ( Only in patients with neurogenic overactive bladder )

  7. The change from baseline in the QOL score [ Time Frame: Baseline and Week 2,6,12,14,18,24 ]
    The change from baseline in the QOL score

  8. The change from baseline in the OABSS total summary score [ Time Frame: Baseline and Week 2,6,12,14,18,24 ]
    The change from baseline in the OABSS total summary score



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. All patients should provided written informed consent.
  2. Patients with idiopathic or neurogenic overactive bladder with symptoms of episodes of urgency, incontinence, micturition and nocturia,( maintaining spontaneous voiding ).
  3. Patients must experienced 3 or more urgency UI episodes in a 3-day period and an average of 8 or moremicturitions per day.
  4. Patients were inadequately treated with prior anticholinergic therapy due to inadequate efficacy or intolerable side effects.
  5. Anticholinergic use was not permitted within 7 days of screening or patients treated with anticholinergics at baseline continued at a stable dose throughout the study.

Exclusion Criteria:

  1. Patients with difficulty urinating have a PVR of 50 ml or more.
  2. Patients requiring indwelling catheter or clean intermittent catheterization (CIC).
  3. Female patients who is pregnant, lactating, or with child-bearing potential without contraception.
  4. People who are allergic to study drugs or its ingredients or allergic should be excluded.
  5. Current severe cardiovascular disease ongoing clinical instability.
  6. Renal insufficiency and serum creatinine greater than 1.5 times the upper limit of normal.
  7. Liver diseases, ALT or AST greater than 2 times the upper limit of normal.
  8. Alcohol or drug abusers.
  9. Have participated in the clinical trials of other drugs within a month.
  10. Any previous botulinum toxin therapy for a urologic condition within 6 months.
  11. Urinary tract infection (① patients with symptoms of fever, pyuria, urinary frequency, urgency or dysuria etc.; ② positive urine culture ( bacterial colony counts > 10^5 cfu/ml) or urine WBC> 10/ HPF; meet both of ① and ② or any one can be diagnosed as a urinary tract infection).
  12. Patients accompany of bladder stones, ureteral stones or urethral; or lithotripsy performed within 3 months.
  13. Patients of bladder or prostate cancer.
  14. Patients with diabetes.
  15. Patients with aminoglycoside antibiotics or neuromuscular junction function drugs within one week.
  16. Any medical condition that may lead the subject to increased risk with exposure to Botulinum Toxin Type A, including myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis, or any other disorder that might have interfered with neuromuscular function.
  17. Patients with bleeding tendency.
  18. Patients have used anticoagulant agents within one week before the first use of study drug.
  19. Investigator's opinion that the subject has a concurrent condition(s) that may put the subject at significant risk, may confound the study results, or may interfere significantly with the conduct of the study.

Layout table for additonal information
Responsible Party: Lanzhou Institute of Biological Products Co., Ltd
ClinicalTrials.gov Identifier: NCT02786407     History of Changes
Other Study ID Numbers: HengLi004
First Posted: June 1, 2016    Key Record Dates
Last Update Posted: January 3, 2018
Last Verified: December 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Lanzhou Institute of Biological Products Co., Ltd:
overactive bladder
Botulinum Toxin Type A for Injection

Additional relevant MeSH terms:
Layout table for MeSH terms
Botulinum Toxins
Botulinum Toxins, Type A
Urinary Bladder, Overactive
Urinary Bladder Diseases
Urologic Diseases
Lower Urinary Tract Symptoms
Urological Manifestations
Signs and Symptoms
abobotulinumtoxinA
Acetylcholine Release Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Neuromuscular Agents
Peripheral Nervous System Agents